ZLAB

Zai Lab Limited NASDAQ

Healthcare ·Biotechnology ·CN · zailaboratory.com

$21.22

Mkt Cap $2.3B

52w Low $15.96 18.5% of range 52w High $44.34

50d MA $20.20 200d MA $24.66

P/E (TTM) -13.5x

EV/EBITDA -9.3x

P/B 3.3x

Debt/Equity 0.3x

ROE -24.5%

P/FCF -12.2x

RSI (14) —

ATR (14) —

Beta 0.86

50d MA $20.20

200d MA $24.66

Avg Volume 762.1K

About

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	1M%	Guide ▲★
Feb 26, 2026	AMC	-0.44	-0.46	-4.5%	19.69	-3.8%	-2.4%	-6.5%	-10.0%	-2.1%	-2.0%	-9.3%	—
Nov 6, 2025	AMC	-0.28	-0.33	-17.9%	23.15	-4.3%	-5.4%	-5.4%	-5.0%	-5.5%	-6.1%	-17.7%	—
Aug 7, 2025	AMC	-0.37	-0.37	+0.0%	34.08	-0.2%	+2.6%	+1.7%	+0.7%	+4.5%	+2.5%	-8.1%	—
May 8, 2025	AMC	-0.50	-0.45	+10.0%	29.14	+3.3%	+0.3%	+0.9%	-1.8%	-3.4%	-1.3%	+30.0%	—
Feb 27, 2025	AMC	-0.61	-0.80	-31.1%	34.38	-4.1%	+0.8%	-7.7%	-1.1%	+4.5%	+2.9%	+5.1%	—
Nov 12, 2024	AMC	-0.75	-0.42	+44.0%	28.96	+3.9%	+3.4%	-7.9%	-6.6%	-13.1%	-9.7%	-7.7%	—
Aug 6, 2024	AMC	-0.66	-0.82	-24.2%	18.11	+13.2%	-8.1%	-4.7%	-10.2%	-10.2%	-10.3%	+8.4%	—
May 8, 2024	AMC	-0.93	-0.55	+40.9%	16.57	+21.0%	+26.8%	+21.2%	+29.9%	+30.1%	+25.8%	+20.7%	—
Feb 27, 2024	AMC	-0.87	-0.98	-12.6%	22.49	-3.1%	-7.5%	-6.7%	-6.2%	-9.2%	-15.9%	-28.8%	—
Nov 7, 2023	AMC	-0.94	-0.71	+24.5%	28.31	+8.3%	+6.0%	-0.5%	-0.5%	-4.5%	+0.1%	-2.9%	—
Aug 7, 2023	AMC	-0.74	-1.25	-68.9%	26.46	-4.7%	-8.6%	-0.3%	-2.7%	-2.6%	-3.4%	+6.6%	—
Mar 1, 2023	AMC	-1.04	-0.65	+37.5%	40.38	-9.2%	-8.5%	+1.3%	-1.3%	-5.4%	-9.3%	-17.6%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 18	JP Morgan	Maintains	Overweight → Overweight	—	$19.02	$18.98	-0.2%	-1.0%	-2.2%	-4.9%	-7.4%	-8.1%
Feb 27	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$19.69	$18.95	-3.8%	-2.4%	-6.5%	-10.0%	-2.1%	-2.0%
Feb 5	JP Morgan	Maintains	Overweight → Overweight	—	$17.00	$17.34	+2.0%	-0.1%	+5.9%	+8.5%	+15.0%	+11.9%
Aug 11	Citigroup	Maintains	Buy → Buy	—	$34.96	$34.72	-0.7%	-0.9%	-1.9%	+1.9%	-0.1%	+2.2%
Jun 30	Leerink Partners	Maintains	Outperform → Outperform	—	$34.74	$36.26	+4.4%	+0.7%	+1.2%	+2.2%	+4.8%	+2.1%
Mar 27	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$33.91	$35.04	+3.3%	+6.7%	+10.0%	+6.6%	+10.0%	+7.4%
Mar 13	JP Morgan	Maintains	Overweight → Overweight	—	$35.43	$35.45	+0.1%	+2.0%	+7.8%	+8.2%	+7.0%	+7.3%
Mar 3	BofA Securities	Downgrade	Buy → Neutral	—	$34.64	$33.70	-2.7%	-8.4%	-1.8%	+3.7%	+2.2%	+5.1%
Oct 21	JP Morgan	Maintains	Overweight → Overweight	—	$27.49	$27.43	-0.2%	+1.9%	+4.8%	+5.3%	+20.7%	+17.8%
Jul 12	JP Morgan	Maintains	Overweight → Overweight	—	$17.84	$18.27	+2.4%	+1.1%	+0.9%	+4.1%	+5.0%	+5.4%
Feb 29	Citigroup	Maintains	Buy → Buy	—	$20.80	$21.60	+3.8%	+0.9%	+1.4%	-1.8%	-9.1%	-4.8%
Nov 30	JP Morgan	Maintains	Overweight → Overweight	—	$27.10	$27.97	+3.2%	+0.7%	+1.5%	-0.4%	-1.1%	+1.5%
Oct 26	Goldman Sachs	Maintains	Buy → Buy	—	$24.06	$23.65	-1.7%	-4.5%	-2.3%	+5.5%	+4.7%	+2.9%
Oct 26	Citigroup	Maintains	Buy → Buy	—	$24.06	$23.65	-1.7%	-4.5%	-2.3%	+5.5%	+4.7%	+2.9%
Oct 17	JP Morgan	Maintains	Overweight → Overweight	—	$25.03	$25.00	-0.1%	-0.4%	-1.8%	-6.1%	-4.5%	-4.0%
Oct 9	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$23.85	$23.88	+0.1%	-1.0%	+0.6%	+4.7%	-1.1%	+5.7%
Sep 18	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$25.76	$26.30	+2.1%	+0.1%	-1.7%	-1.4%	-6.9%	-5.0%
Jun 12	BofA Securities	Maintains	Buy → Buy	—	$28.16	$28.26	+0.4%	-1.9%	-1.9%	-1.8%	+1.1%	+3.3%
May 11	Citigroup	Maintains	Buy → Buy	—	$37.51	$36.86	-1.7%	-2.2%	-10.5%	-10.3%	-10.2%	-10.7%
Mar 16	JP Morgan	Maintains	Overweight → Overweight	—	$32.00	$31.58	-1.3%	+7.1%	+5.8%	-5.6%	+1.6%	-4.2%
Nov 18	JP Morgan	Maintains	Overweight → Overweight	—	$35.53	$35.00	-1.5%	-1.6%	-1.8%	-6.0%	-6.1%	-10.7%
Nov 11	Citigroup	Maintains	Buy → Buy	—	$30.39	$30.69	+1.0%	+24.3%	+21.6%	+27.4%	+16.4%	+16.9%
Aug 9	Citigroup	Maintains	Buy → Buy	—	$47.08	$47.50	+0.9%	-4.0%	-5.0%	-4.4%	-6.2%	-2.8%
May 12	Citigroup	Maintains	Buy → Buy	—	$25.03	$25.03	+0.0%	+8.2%	+32.7%	+31.6%	+41.2%	+37.9%
May 11	SVB Leerink	Maintains	Outperform → Outperform	—	$26.24	$30.00	+14.3%	-4.6%	+3.2%	+26.6%	+25.5%	+34.7%
Apr 21	SVB Leerink	Maintains	Outperform → Outperform	—	$45.00	$45.70	+1.6%	-6.2%	-3.6%	+2.0%	-8.4%	-5.0%
Apr 4	JP Morgan	Maintains	Overweight → Overweight	—	$45.47	$46.01	+1.2%	+9.3%	+5.6%	+3.4%	+2.6%	-4.3%
Mar 2	SVB Leerink	Maintains	Outperform → Outperform	—	$52.55	$50.93	-3.1%	-0.0%	-20.3%	-22.9%	-29.2%	-30.1%
Dec 15	JP Morgan	Maintains	Overweight → Overweight	—	$62.69	$59.34	-5.3%	-12.4%	+5.7%	+16.9%	+8.8%	+10.4%
Nov 11	Citigroup	Maintains	Buy → Buy	—	$87.82	$87.51	-0.4%	-3.0%	-3.0%	-2.1%	+3.6%	+3.3%
Nov 10	SVB Leerink	Maintains	Outperform → Outperform	—	$86.69	$87.62	+1.1%	+1.3%	-1.7%	-1.8%	-0.8%	+5.0%
Oct 12	Bernstein	Maintains	Market Perform → Perform	—	$101.70	$100.80	-0.9%	-2.1%	+0.4%	+0.5%	+0.3%	-2.5%
Jun 1	SVB Leerink	Maintains	Outperform → Outperform	—	$177.66	$177.91	+0.1%	+1.3%	-0.5%	-0.8%	-3.5%	-3.6%
Apr 14	SVB Leerink	Maintains	Outperform → Outperform	—	$161.29	$159.01	-1.4%	+2.2%	+1.4%	+1.9%	+1.9%	-6.5%
Feb 3	SVB Leerink	Maintains	Outperform → Outperform	—	$176.78	$174.91	-1.1%	-1.9%	+0.8%	+0.4%	+3.9%	+4.0%
Sep 10	SVB Leerink	Maintains	Outperform → Outperform	—	$78.50	$79.01	+0.6%	-5.7%	-4.2%	-1.4%	+0.4%	+5.2%
Dec 30	Citigroup	Maintains	Buy → Buy	—	$40.25	$42.00	+4.3%	+0.4%	+3.3%	+5.9%	-1.5%	-2.9%
Sep 4	China Renaissance	Maintains	Buy → Buy	—	$32.54	$33.65	+3.4%	+2.0%	+3.6%	+5.6%	+9.1%	+7.2%
Jul 5	Macquarie	Maintains	Outperform → Outperform	—	$36.33	$36.54	+0.6%	-0.1%	-1.3%	-1.2%	-0.7%	-1.5%
Jan 29	Credit Suisse	Maintains	Outperform → Outperform	—	$26.05	$26.31	+1.0%	+5.0%	+3.5%	+3.6%	+4.5%	+4.4%
Feb 14	JP Morgan	Maintains	Overweight → Overweight	—	$22.00	$23.60	+7.3%	+10.1%	+8.6%	+6.8%	+10.2%	+9.0%
Feb 14	JP Morgan	Upgrade	Neutral → Overweight	—	$22.00	$23.60	+7.3%	+10.1%	+8.6%	+6.8%	+10.2%	+9.0%
Oct 16	JP Morgan	Maintains	Neutral → Neutral	—	$32.19	$31.57	-1.9%	-0.6%	-4.2%	-11.0%	-14.3%	-12.3%

Recent Filings

8-K

Zai Lab Limited -- 8-K Filing

Zai Lab reported 2025 fourth-quarter and full-year financial results, demonstrating continued operational progress under CEO Samantha Du's leadership across its NASDAQ and Hong Kong Exchange listings.

Feb 26

Data updated apr 27, 2026 11:46am · Source: massive.com